Dyslexia Treatment Market Report 2026

The dyslexia treatment market size has grown strongly in recent years. It will grow from $30.17 billion in 2025 to $32.27 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to learning disability awareness, special education programs, school-based intervention adoption, literacy curriculum development, therapist availability.

The dyslexia treatment market size is expected to see strong growth in the next few years. It will grow to $40.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to digital education platforms growth, personalized learning models, early screening programs, home-based therapy expansion, inclusive education policies. Major trends in the forecast period include growing adoption of structured literacy programs, increased use of multisensory learning approaches, expansion of digital learning and assistive tools, rising focus on early childhood intervention, integration of speech and occupational therapies.

The increasing prevalence of chronic diseases is expected to drive the growth of the dysautonomia (autonomic dysfunction) market in the coming years. Chronic disease refers to a long-lasting health condition that persists for more than three months. The rise in chronic disease is influenced by factors such as the growing occurrence of multimorbidity, where individuals are diagnosed with multiple chronic conditions simultaneously. Dysautonomia (autonomic dysfunction) plays a significant role in chronic diseases by impairing the body’s ability to regulate essential functions like heart rate, blood pressure, and digestion, often worsening symptoms and complicating disease management. For instance, in April 2025, according to the NHS Confederation, a UK-based national association, it is estimated that by 2035, 17% of the UK population could be living with four or more chronic conditions. Therefore, the increasing prevalence of chronic diseases is driving the growth of the dysautonomia (autonomic dysfunction) market.

The rising prevalence of neurological disorders is expected to propel the growth of the dyslexia treatment market going forward. Neurological disorders are medical conditions that impact the central and peripheral nervous system, including the brain, spinal cord, and nerves. The increase in neurological disorders is driven by aging populations, lifestyle changes, environmental factors, and improved diagnostic technologies that enhance detection and reporting. The dyslexia treatment market supports this trend by providing multisensory learning, cognitive training, and targeted interventions that promote neuroplasticity and improve cognitive processing for individuals facing neurological-related learning challenges. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, and this number is projected to rise to 13.8 million by 2060. Therefore, the growing prevalence of neurological disorders is driving the growth of the dyslexia treatment market.

Major companies operating in the dyslexia treatment market are focusing on developing advanced solutions such as white noise features to improve focus, reduce distractions, and enhance reading fluency for neurodivergent learners. A white noise feature is an auditory tool that provides consistent background sound to support concentration and cognitive processing, particularly benefiting individuals with dyslexia, ADHD, and related learning differences. For instance, in October 2024, Promova Limited, a US-based technology company, launched Dyslexia Mode 2.0, an upgraded accessibility feature designed to improve language learning for individuals with dyslexia and other neurodiverse conditions. The enhanced version includes adjustable font sizes, color-shift options to reduce visual contrast, and removal of all-caps text to improve readability, along with supportive auditory elements such as white noise. Developed with expert guidance, including input from dyslexic designer Martin Pysny, Dyslexia Mode 2 provides a more inclusive and comfortable learning environment tailored to users with unique cognitive and visual processing needs.

Major companies operating in the dyslexia treatment market are Pfizer Inc., Astrazeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Purdue Pharma, Apotex Corporation, Endo International Plc, Amneal Pharmaceuticals LLC, Unither Pharmaceuticals LLC, RPG Life Sciences Ltd., Jubilant Pharma Limited, Breckenridge Pharmaceutical Inc., Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd, Lexia Learning Systems LLC, Wallace Pharmaceuticals Ltd., Ironshore Pharmaceuticals Inc., DK Pharmachem Pvt Ltd., Speechify Inc., Lingit AS, Lyfta, Nessy Learning Ltd.

North America was the largest region in the dyslexia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyslexia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dyslexia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dyslexia treatment market by increasing costs of imported educational software, assistive learning devices, and therapy materials. Educational institutions and rehabilitation centers in developed regions are most affected. These tariffs increase program costs by raising licensing, device procurement, and instructional material expenses, potentially limiting adoption in public education systems. However, they encourage local development of educational tools and digital platforms, supporting region-specific learning solutions and cost-effective intervention models.

The dyslexia treatment market research report is one of a series of new reports that provides dyslexia treatment market statistics, including dyslexia treatment industry global market size, regional shares, competitors with a dyslexia treatment market share, detailed dyslexia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the dyslexia treatment industry. This dyslexia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dyslexia treatment encompasses a variety of strategies and interventions aimed at helping individuals with dyslexia improve their reading, writing, and spelling abilities. This often involves specialized educational programs, such as structured literacy and multisensory instruction, which integrate visual, auditory, and kinesthetic techniques to reinforce learning. Key elements of effective dyslexia treatment include regular practice, personalized support, and early intervention.

The main types of dyslexia include double-deficit dyslexia, visual dyslexia, phonological dyslexia, and others. Double-deficit dyslexia is characterized by difficulties in both phonological processing (the ability to break words into sounds) and naming speed (the ability to quickly name letters and numbers). Therapies for dyslexia include occupational therapy, speech therapy, and cognitive behavioral therapy, while medications used may include cyclizine, meclizine, dimenhydrinate, methylphenidate, and others. Distribution channels include hospital pharmacies, retail pharmacies, and others, with end users such as psychiatric institutions, rehabilitation centers, home care settings, and more.

The dyslexia treatment market consists of revenues earned by entities by services such as literacy programs, multisensory interventions, assistive technologies, individualized education plans, cognitive training, and therapies targeting visual and auditory processing skills. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyslexia treatment market also includes sales of assistive listening devices, phonological processing tools, digital pens and notetaking devices, eye-tracking devices, and multi-sensory learning tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.